The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia (Journal article)
Agouridis, A. P./ Tsimihodimos, V./ Filippatos, T. D./ Dimitriou, A. A./ Tellis, C. C./ Elisaf, M. S./ Mikhailidis, D. P./ Tselepis, A. D.
Objective: Mixed dyslipidemia, oxidative stress and inflammation are related to a high risk for cardiovascular events. The aim of this open-label randomized study was to compare the effects of high-dose rosuvastatin, low-dose rosuvastatin plus fenofibrate and low-dose rosuvastatin plus omega 3 fatty acids on inflammation and oxidative stress indices in patients with mixed dyslipidemia. Methods: Ninety patients with mixed dyslipidemia participated in the study. Patients were randomly allocated to receive rosuvastatin 40 mg (n = 30, group R), rosuvastatin 10 mg plus fenofibrate 200 mg (n = 30, group RF) or rosuvastatin 10 mg plus omega 3 fatty acids 2 g daily (n = 30, group R Omega). Plasma and high-density lipoprotein (HDL)-associated lipoprotein-associated phospholipase A2 (LpPLA2) activities, high-sensitivity C reactive protein (hsCRP), plasma isoprostane and paraoxonase (PON1) activities were measured at baseline and after 3 months of treatment. Results: Serum concentrations of non-HDL cholesterol and low-density lipoprotein cholesterol (LDL-C) were significantly reduced in all study groups. However, these changes were more pronounced in the rosuvastatin monotherapy group. In all treatment groups a significant reduction in total plasma LpPLA2 activity was observed (by 41, 38 and 30% for groups R, RF and RW, respectively). This decrease was greater in the R and RF groups compared with the RW combination (p < 0.05). HDL-LpPLA2 activity was increased more in the RF group (+43%) compared with the R and RW groups (+ 18% and + 35%, respectively; p < 0.05 for both comparisons). In all treatment groups there was a nonsignificant reduction in plasma 8-iso-PGF2 alpha levels. A 53% reduction of hsCRP levels was observed in the R group, while in the RF and RW groups the reduction was 28 and 23%, respectively (p < 0.05 and p < 0.01 for the comparisons of group R with groups RF and RW, respectively). No significant changes were observed in PON activities in all treatment groups. Conclusion: The greater non-HDL-C- and LDL-C-lowering efficiency of rosuvastatin monotherapy along with its more potent effect on LpPLA2 activity and hsCRP levels indicate that this regimen is a better treatment option for patients with mixed dyslipidemia.
|Institution and School/Department of submitter:||Πανεπιστήμιο Ιωαννίνων. Σχολή Θετικών Επιστημών. Τμήμα Χημείας|
|Keywords:||fenofibrate,high sensitivity c-reactive protein,isoprostane 8-iso-prostaglandin f2alpha,lipoprotein-associated phospholipase a2,omega 3 fatty acids,rosuvastatin,c-reactive protein,coronary-heart-disease,lipoprotein-associated phospholipase-a2,activating-factor-acetylhydrolase,low-density-lipoprotein,middle-aged men,n-3 fatty-acids,cardiovascular-disease,metabolic syndrome,follow-up|
|Link:||<Go to ISI>://000296981400002|
|Appears in Collections:||Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)|
Files in This Item:
There are no files associated with this item.
Please use this identifier to cite or link to this item:This item is a favorite for 0 people.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.